Sitagliptin-induced bilateral Achilles tendinitis

Sitagliptin (Januvia) is a widely used oral dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of diabetes. Studies suggest that the drug is well-tolerated and no musculoskeletal side effects have been reported [1]. A 56-year-old female developed bilateral Achilles tendinitis 4 months after...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 53; no. 4; p. 630
Main Authors Bussey, Melissa R, Emanuele, Mary Ann, Lomasney, Laurie M, Tehrani, Rodney
Format Journal Article
LanguageEnglish
Published England 01.04.2014
Subjects
Achilles Tendon - pathology
Diabetes Mellitus - drug therapy
Female
Humans
Hypoglycemic Agents - adverse effects
Magnetic Resonance Imaging
Middle Aged
Pyrazines - adverse effects
Sitagliptin Phosphate
Tendinopathy - chemically induced
Tendinopathy - pathology
Triazoles - adverse effects
Online AccessGet full text

Cover

More Information
Summary:Sitagliptin (Januvia) is a widely used oral dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of diabetes. Studies suggest that the drug is well-tolerated and no musculoskeletal side effects have been reported [1]. A 56-year-old female developed bilateral Achilles tendinitis 4 months after restarting sitagliptin. There was no trauma to the Achilles tendons, but she had recently started a low-impact exercise programme; she stopped exercising with no relief.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ObjectType-Article-2
ObjectType-Feature-1
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/ket395